KNSA
Kiniksa Pharmaceuticals International plc. - Class A (KNSA)
Healthcare • NASDAQ • $79.03+0.71%
- Symbol
- KNSA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $79.03
- Daily Change
- +0.71%
- Market Cap
- $5.99B
- Trailing P/E
- 77.53
- Forward P/E
- 47.45
- 52W High
- $82.94
- 52W Low
- $32.89
- Analyst Target
- $98.00
- Dividend Yield
- N/A
- Beta
- 0.09
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. K…
Company websiteResearch KNSA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.